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Objectives. The second Primary Angioplasty in Myocardial
Infarction (PAMI-II) study evaluated the hypothesis that primary
percutaneous transluminal coronary angioplasty (PTCA), with
subsequent discharge from the hospital 3 days later, is safe and
cost-effective in low risk patients.
Background. In low risk patients with myocardial infarction
(MI), few data exist regarding the need for intensive care and
noninvasive testing or the appropriate length of hospital stay.
Methods. Patients with acute MI underwent emergency cathe-
terization with primary PTCA when appropriate. Low risk pa-
tients (age <270 years, left ventricular ejection fraction >45%,
one- or two-vessel disease, successful PTCA, no persistent arrhyth-
mias) were randomized to receive accelerated care (admission to a
nonintensive care unit and day 3 hospital discharge without nonin-
vasive testing [n 5 237] or traditional care [n 5 234]).
Results. Patients who received accelerated care had similar
in-hospital outcomes but were discharged 3 days earlier (4.2 6 2.3
vs. 7.1 6 4.7 days, p 5 0.0001) and had lower hospital costs
($9,658 6 5,287 vs. $11,604 6 6,125 p 5 0.002) than the patients
who received traditional care. At 6 months, accelerated and tradi-
tional care groups had a similar rate of mortality (0.8% vs. 0.4%, p 5
1.00), unstable ischemia (10.1% vs. 12.0%, p 5 0.52), reinfarction
(0.8% vs. 0.4%, p 5 1.00), stroke (0.4% vs. 2.6%, p 5 0.07), congestive
heart failure (4.6% vs. 4.3%, p 5 0.85) or their combined occurrence
(15.2% vs. 17.5%, p 5 0.49). The study was designed to detect a 10%
difference in event rates; at 6 months, only a 2.3% difference was
measured between groups, indicating an actual power of 0.19.
Conclusions. Early identification of low risk patients with MI al-
lowed safe omission of the intensive care phase and noninvasive
testing, and a day 3 hospital discharge strategy, resulting in substan-
tial cost savings.
(J Am Coll Cardiol 1998;31:967–72)
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Serious complications, including death, usually occur within
48 h of myocardial infarction (MI) (1–6), well before nonin-
vasive testing is performed. Numerous studies have described
methods of determining clinical risk, (1–3,6–11); however,
none have prospectively tested this information in the early
management of patients with MI. Moreover, national guide-
lines recommend that patients with MI undergo extensive
observation, monitoring and noninvasive testing (12), and 70%
receive catheterization (13,14). Although angiographic criteria,
including Thrombolysis in Myocardial Infarction (TIMI) flow
grades (15), multivessel disease and left ventricular ejection
fraction (LVEF), are of prognostic importance (16–22), cath-
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eterization is often performed just before hospital discharge.
Delayed catheterization data cannot be used to discharge
patients early, and the potential benefits are greatly diminished
because most deaths will have occurred before hospital dis-
charge (4,23,24).
The purpose of the second Primary Angioplasty in Myocar-
dial Infarction (PAMI-II) study was to determine whether
clinical and catheterization data could be used to prospectively
identify low risk patients with MI who could safely go without
intensive care and noninvasive testing and be discharged from
the hospital on day 3.
Methods
Clinical centers. This study was conducted in 34 clinical
centers in five countries. The study sites were diverse and
included urban and rural settings and teaching and nonteach-
ing hospitals. Two participating centers performed emergency
percutaneous transluminal coronary angioplasty (PTCA) pro-
cedures but had no elective PTCA or coronary artery bypass
graft surgery programs. Physicians and catheterization labora-
tory staff were available on a 24-h basis.
Study group. Patient selection required symptom onset
,12 h in duration and evidence of MI as reflected by electro-
cardiographic (ECG) ST segment elevation in at least two
contiguous leads; the presence of left bundle branch block or a
nondiagnostic ECG; or angiographic evidence of MI that was
determined by the presence of an occluded vessel and regional
ventricular dysfunction. Patients were not enrolled if they had
cardiogenic shock or clinical indications for intraaortic balloon
pumping in the emergency room; if there was a lack of
peripheral vascular access; or if there was a bleeding risk
prohibiting the use of aspirin and heparin. The study was
approved by each center’s institutional review board, and all
patients gave written, informed consent.
Catheterization and PTCA procedure. Patients were
treated with chewable aspirin (325 mg), a 10,000-U bolus of
heparin, intravenous nitroglycerin and, in the absence of
contraindications, intravenous beta-adrenergic blocking agents.
Emergency catheterization was performed using ionic contrast
agents to avoid thrombolytic complications (25). It was sug-
gested that PTCA not be performed if the patient was unlikely
to benefit (i.e., infarct-related vessels with #70% stenosis or
those supplying a very small amount of myocardium); these
patients were treated medically. Bypass surgery was recom-
mended for patients with unprotected left main coronary
artery stenoses .60% or severe three-vessel disease with
spontaneous reperfusion of the infarct-related vessel. PTCA
was recommended for all others. Additional heparin was given
to achieve an activated clotting time between 350 and 400 s
(26,27), which was maintained throughout the procedure. A
visual estimation of LVEF by contrast ventriculography was
used for acute risk stratification.
Acute risk stratification and randomization. Based on
clinical and angiographic features after PTCA, the operator
stratified patients into low and high risk groups. Low risk status
required that all the following criteria be met: age #70 years,
no persistent arrhythmias after reperfusion (requiring lido-
caine infusion or pacemaker), one- or two-vessel disease
($70% stenosis), LVEF .45% and successful PTCA of a
native coronary artery. Patients identified as low risk were
randomized to receive accelerated care versus traditional care.
Accelerated care consisted of 1) admission to a nonintensive
care unit that was typically used for patients who would have
elective PTCA, and 2) full-dose heparin for 48 h, followed by
half-dose heparin for an additional 12 h to avoid a rebound
hypercoagulable state (27,28). Noninvasive testing was not
recommended, and the patients were to be discharged on day
3 in the absence of clinical contraindications, such as arrhyth-
mia, hypotension, chest pain, congestive heart failure (CHF),
stroke, renal insufficiency, sepsis or other conditions requiring
in-hospital treatment. Traditional care consisted of admission
to a coronary care unit, noninvasive testing that was routine for
the enrolling institution, intravenous heparin for 72 h and a
hospital stay of at least 5 days.
Patients who did not meet low risk criteria were considered
high risk and were randomized to receive or not receive
prophylactic intraaortic balloon counterpulsation. The results
in this group have been previously reported (29).
End points and definitions. The primary end point was the
combined occurrence of death, reinfarction, unstable ischemia,
stroke or CHF by 6 months. These events were selected
because they are thought to be “unsatisfactory outcomes” after
reperfusion therapy (30). The null hypothesis of this study was
one of no difference between accelerated and traditional care
groups regarding the primary end point (expected event rate of
15%). To detect an absolute difference of 10% with an alpha
level of 0.05 and a power of 0.8, a minimum of 400 patients
were required for a two-tailed test.
Angioplasty success was defined as ,50% stenosis and TIMI
flow grade 2 or 3; reocclusion as a previously patent (TIMI flow
grade 2 or 3) infarct-related vessel that demonstrated TIMI
flow grade 0 or 1 with $90% stenosis; CHF as Killip class II to
IV (31); reinfarction as recurrent clinical symptoms in associ-
ation with an increase in creatine kinase, MB fraction (CK-
MB) above its previous nadir; and recurrent unstable ischemia
as clinical symptoms associated with ECG changes, hypoten-
sion, new murmur, CK-MB elevation or the need for emer-
gency revascularization.
Abbreviations and Acronyms
CHF 5 congestive heart failure
CK-MB 5 creatine kinase, MB fraction
ECG 5 electrocardiogram, electrocardiographic
LVEF 5 left ventricular ejection fraction
MI 5 myocardial infarction
PAMI-II 5 second Primary Angioplasty in Myocardial Infarction
study
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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Data collection. Data were collected prospectively by re-
search nurses at each of the 34 clinical centers. Data were
audited by an independent study coordinator who traveled to
sites to randomly cross reference case report forms and
medical records. Angiographic data were reported on the basis
of the operator’s visual assessment, because this interpretation
was used for risk stratification, subsequent randomization and
clinical decision making. Data were abstracted from hospital
bills obtained from U.S. sites to determine in-patient charges,
which were then converted to cost using each hospital’s
Medicare charge/cost ratio. Follow-up data from hospital,
office records and telephone calls were submitted on standard-
ized case report forms 1 and 6 months after enrollment.
On-site clinical audits were performed in 49.6% of cases, and
the remaining cases were audited by reviewing copies of
hospital records. Discrepancies between the site and study
auditor were adjudicated by two or three additional medical
personnel who had no knowledge of the the randomization
scheme.
Statistical analysis. Data were entered into a commercially
available data base package (Microsoft Access), and statistical
analyses were performed using conventional software (SAS).
When comparing treatment groups, the chi-square or two-
tailed Fisher exact test was used for categoric variables and the
t test for continuous variables (Mann-Whitney U test for
continuous variables with nonnormal distribution). Differences
in event-free survival were determined using the Kaplan-Meier
method.
Results
Overall study group. Between September 1993 and Janu-
ary 1995, 1,100 patients were enrolled and underwent cathe-
terization at 34 clinical centers. Angiographic information was
used to decide the appropriate therapy for each patient:
Primary PTCA was performed in 982 patients (89%), bypass
surgery alone in 53 (5%) and medical therapy alone in 65
(6%). PTCA was successful in 96.1% of attempts and resulted
in TIMI flow grade 3 in 92.9% of vessels. Emergency bypass
surgery for failed PTCA was required in 0.5% of patients.
Overall, in-hospital mortality was 2.9% (2.8% for PTCA, 5.7%
for bypass surgery and 1.5% for medical). Stroke was observed
in 1.0%, reinfarction in 1.8%, recurrent ischemia in 10.3% and
CHF in 8.5% of patients.
Risk stratification and randomization. Of the 1,100 pa-
tients recruited, 192 were not randomized (48 of whom were
considered low risk but were treated medically) and 437 were
randomized in the high risk strata (29). Four hundred seventy-
one patients were stratified as low risk and randomized to
receive accelerated care (n 5 237) or traditional care (n 5
234). Baseline clinical and angiographic characteristics were
similar between the two groups (Table 1). Patients randomized
to receive accelerated care had no increase in the incidence of
in-hospital adverse events, death (0.4% vs. 0.4%, p 5 1.00),
reinfarction (0.4% vs. 0.4%, p 5 1.00), unstable ischemia
(5.9% vs. 8.1%, p 5 0.35), stroke (0% vs. 1.7%, p 5 0.06), CHF
(4.2% vs. 3.9%, p 5 0.84) or the combined end point (10.1%
vs. 12.8%, p 5 0.36).
Of the 237 patients randomized to receive accelerated care,
protocol-designated contraindications for early discharge were
present in 59 (25%). These included death in 0.4%, transient
ischemic attack in 0.4%, chest pain (either ischemic or nonisch-
emic) in 7.7%, CHF in 1.7%, arrhythmia in 8.5%, bleeding in
3.0% and fever in 3.4%. Of the 178 patients eligible for early
hospital discharge, 142 (80%) were discharged on day 3.
Reluctance to discharge early was observed more frequently in
foreign sites; within the United States, 137 (92%) of 149
eligible patients were discharged on day 3. Overall, patients
randomized to receive accelerated care had a shorter length of
hospital stay (4.2 6 2.3 vs. 7.1 6 4.7 days, p , 0.0001) and
lower hospital cost ($9,658 6 $5,287 vs. $11,604 6 $6,125, p 5
0.002) owing to reduced charges for room and board, phar-
macy, laboratory and cardiac testing (Fig. 1).
Follow-up data at 6 months are available in 452 (96.0%) of
471 low risk patients. Readmission for recurrent unstable
ischemia or MI occurred in 4.2% and 3.9% (p 5 0.84) and
target vessel revascularization was performed in 9.8% and
8.6% (p 5 0.66) of accelerated and traditional care groups,
respectively. By 6 months, the timing and frequency of death
(0.8% vs. 0.4%, p 5 1.00), reinfarction (0.8% vs. 0.4%, p 5
1.00), unstable ischemia (10.1% vs. 12.0%, p 5 0.52), stroke
(0.4% vs. 2.6%, p 5 0.07), CHF (4.6% vs. 4.3%, p 5 0.85) or
the combined occurrence of any event (15.2% vs. 17.5%, p 5
0.49) were similar between accelerated and traditional care
groups (Fig. 2).
A priori, sample size was calculated to detect a 10%
difference in the primary end point between groups. However,
our results indicate a 2.3% to 2.7% difference between accel-
Table 1. Clinical and Angiographic Characteristics in Low Risk






(n 5 234) p Value
Age (yr) 55 6 10 56 6 10 0.21
Male 77.6% 75.2% 0.54
Previous MI 11.2% 10.4% 0.79
Hypertension 37.7% 37.6% 1.0
Diabetes, insulin-dependent 2.2% 3.9% 0.27
Thrombolytic eligible 75.7% 80.9% 0.18
Diseased vessels
1 75.6% 74.8% 0.83
2 23.1% 23.1%
3* 1.3% 2.1%
Post-PTCA TIMI flow grade
0–1* 0.4% 0.4% 0.54
2 1.3% 1.7%
3 98.3% 97.8%
Post-PTCA % stenosis 20 6 13 20 6 12 0.71
*Risk stratification deviations by physician. Data presented are mean
value 6 SD or percent of patients. MI 5 myocardial infarction; PTCA 5
percutaneous transluminal coronary angioplasty; TIMI 5 Thrombolysis In
Myocardial Infarction.
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erated and traditional care groups. Thus, the actual power of
the statistical test was 0.24 for in-hospital and 0.19 at 6 months
(alpha 0.05).
Discussion
Primary PTCA has been shown to be a safe and effective
method of providing reperfusion therapy for acute MI, and
when compared with thrombolysis, it reduces the risk of
recurrent ischemia (32–34), reinfarction, death and stroke
(35,36). Thus, our focus in the PAMI-II trial was to determine
whether acute catheterization data could be used to risk
stratify patients after primary PTCA, and whether an acceler-
ated hospital course was safe and cost effective in low risk
patients.
Although there is increasing pressure to contain cost and
discharge patients as soon as possible after MI, limited data
exist regarding the safety of early hospital discharge. In a small,
prospective study, 18% of post-thrombolysis patients were
candidates for early discharge. These patients had reduced
hospital expenses, returned to work earlier and had similar
long-term outcomes compared with patients discharged at 7 to
10 days (37). However, this study required that all patients
undergo exercise thallium imaging, and the majority also
underwent catheterization. Mark et al. (18) retrospectively
evaluated thrombolytic-treated patients who survived without
early bypass surgery within the first 4 days of MI. In this cohort,
LVEF .45% with the absence of multivessel disease, sus-
tained arrhythmias or hypotension was predictive of freedom
from late complications. This report first demonstrated the
need for catheterization data to identify patients at risk for
complications, and furthermore estimated that 30% of
thrombolytic-treated patients were suitable for hospital dis-
charge on day 4.
A recent retrospective analysis concluded that patients who
have no clinical complications within the first few days after
thrombolysis may be safely discharged (38). However, in-
hospital events occurring after day 3 in those “uncomplicated”
patients included death (0.9%), stroke (0.3%), reinfarction
(2.4%) and recurrent ischemia (8.9%). Given these data and
other reports (39,40) demonstrating that recurrent ischemia
after thrombolysis occurs unpredictably, it is not surprising that
the investigators opted to keep these uncomplicated patients in
the hospital for an average of 9 days.
In contrast, randomized trials of primary PTCA versus
thrombolysis have demonstrated that PTCA-treated patients
have reduced rates of recurrent ischemia and shorter hospital
stays (32–34,41). The ability of primary PTCA to achieve high
rates of TIMI flow grade 3 (42), with a minimal residual
stenosis (43–46), is likely to be responsible for the low event
rates.
Our study confirmed that low risk patients treated with
primary PTCA have excellent clinical outcomes. Given the low
event rate, it was not surprising that elimination of the
intensive care unit and noninvasive testing, with a day 3
hospital discharge strategy, did not adversely affect outcomes.
This accelerated approach reduced hospital costs by $2,000.
Given the fact that the cost of thrombolytic therapy and
primary PTCA (followed by traditional care) is similar (33,47–
49; Mark DB, Cost effectiveness of thrombolysis vs. angio-
plasty: GUSTO-IIB angioplasty substudy [presented at the
45th Annual Scientific Session of the American College of
Cardiology, Orlando, Florida, March 1996]), this accelerated
care approach may reduce the cost of health care by $293
million annually (assuming that 250,000 patients with MI in the
United States are thrombolytic eligible, that an additional 30%
of patients in this study were thrombolytic ineligible and that
45% would qualify as low risk). However, these savings may be
overestimated, given the recent national trend toward a reduc-
tion in length of hospital stay.
Figure 2. Event-free survival for low risk patients with MI randomized
to receive accelerated versus traditional care. No significant difference
in the timing of events (death, recurrent MI, ischemia, stroke, heart
failure) was found between accelerated (mean [6SE] 160.5 6 3.8) and
traditional care groups (mean [6SE] 177.4 6 4.7) (p 5 0.6). When
mean event-free survival times for the two groups were compared
using the log-rank test or the Wilcoxon test, neither was significant
(p 5 0.602 and 0.631, respectively). Neither test offers evidence that
the two treatments differ with respect to time of event.
Figure 1. Hospital charges for low risk patients with MI. Low risk
patients with MI randomized to receive accelerated care incurred
reduced hospital charges for room and board (R & B), pharmacy (Rx),
laboratory (Lab) and diagnostic testing (Diag). Estimated total cost
(using each hospital’s Medicare charge to cost ratio) favored the
accelerated group by $1,946 ($9,658 6 $5,287 vs. $11,604 6 $6,125,
p 5 0.002) over the traditional care group.
970 GRINES ET AL. JACC Vol. 31, No. 5
EARLY DISCHARGE AFTER PRIMARY ANGIOPLASTY April 1998:967–72
Study limitations. One limitation of this study is the lack of
power to detect small differences in the primary end point.
Only large differences (10%) in event rates could be detected
with the number of patients enrolled in each group. However,
declining hospital reimbursement has driven earlier discharge
of patients with MI, in the absence of much data. This study
was conducted with a sample size of 471 patients, which is
nearly six times larger than the groups in other published trials
(37), thus providing support for the concept of early hospital
discharge.
Clinical implications. After primary PTCA, clinical infor-
mation combined with early catheterization data allows for
identification of low risk patients with MI who can safely
forego intensive care and noninvasive testing, the majority of
whom can be discharged on day 3. Wide application of this
management strategy may result in substantial cost savings.
We thank Diane L. Parsons and Monica L. Kusak for manuscript preparation.
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Economic analysis. William Beaumont Hospital, Royal Oak, Michigan: Tom
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